Scarica l'app Stockscreener
7.64
0.07%
-0.04
Precedente Chiudi:
$7.68
Aprire:
$7.67
Volume 24 ore:
100.93K
Relative Volume:
0.40
Capitalizzazione di mercato:
$177.56M
Reddito:
$155.00K
Utile/perdita netta:
$-30.01M
Rapporto P/E:
-4.5749
EPS:
-1.67
Flusso di cassa netto:
$-11.98M
1 W Prestazione:
+3.30%
1M Prestazione:
+5.43%
6M Prestazione:
+61.24%
1 anno Prestazione:
-27.32%
Intervallo 1D:
$7.51
$7.92
Intervallo di 1 settimana:
$7.19
$8.0602
Portata 52W:
$4.32
$11.03
Inmune Bio Inc Stock (INMB) Company Profile
Nome
Inmune Bio Inc
Settore
Industria
Telefono
(858) 964-3720
Indirizzo
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Confronta INMB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
7.65 | 187.08M | 155.00K | -30.01M | -11.98M | -1.67 |
|
ONC
Beigene Ltd Adr
|
237.12 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.93 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.39 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.37 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.21 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-21 | Iniziato | Alliance Global Partners | Buy |
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-22 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-01 | Iniziato | Robert W. Baird | Outperform |
| 2022-05-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
| 2021-04-21 | Iniziato | B. Riley Securities | Buy |
| 2021-01-22 | Reiterato | Maxim Group | Buy |
| 2020-09-01 | Iniziato | BTIG Research | Buy |
| 2020-07-15 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Inmune Bio Inc Borsa (INMB) Ultime notizie
Where are the Opportunities in (INMB) - news.stocktradersdaily.com
Dimensional Fund Advisors LP Acquires 10,491 Shares of INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio: XPro Trial Readout In Alzheimer’s Disease Offers Big Opportunity (NASDAQ:INMB) - Seeking Alpha
Wells Fargo & Company MN Buys 2,155 Shares of INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio to Attend RBC Healthcare Conference - TipRanks
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
INmune Bio Sets Stage for Key Biotech Insights at RBC Healthcare Conference Next Week - Stock Titan
Raymond James raises INmune Bio stock target to $23 - MSN
Barclays PLC Increases Stake in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - MSN
INmune Bio, Inc. (NASDAQ:INMB) Q1 2025 Earnings Call Transcript - Insider Monkey
INmune Bio’s Earnings Call: Promise and Challenges - TipRanks
Mariner LLC Acquires New Holdings in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
Earnings call transcript: INmune Bio Q1 2025 shows narrowed losses, stock rises - Investing.com
INmune Bio Reports Q1 2025 Results and Updates - TipRanks
INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update - The Manila Times
(INMB) Trading Signals - news.stocktradersdaily.com
INmune Bio appoints new accounting firm By Investing.com - Investing.com Nigeria
INmune Bio appoints new accounting firm - Investing.com
INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
JPMorgan Chase & Co. Has $53,000 Stock Holdings in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th - The Manila Times
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on ... - Eagle-Tribune
Renaissance Technologies LLC Increases Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
LPL Financial LLC Boosts Stock Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average PT from Analysts - Defense World
INmune Bio (INMB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Geode Capital Management LLC Has $1.70 Million Stock Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
A stock that deserves closer examination: INmune Bio Inc (INMB) - uspostnews.com
(INMB) Technical Data - news.stocktradersdaily.com
Inmune Bio Secures Favorable Patentability Opinion for CORDStrom™ - TipRanks
INmune Bio secures key patent opinion for CORDStrom platform By Investing.com - Investing.com South Africa
INmune Bio Receives Favorable Opinion from USPTO on CORDStrom Patent Application - marketscreener.com
INmune Bio Inc. Achieves Key Patent Milestone for CORDStrom™ Cell Therapy Platform - Nasdaq
INmune Bio secures key patent opinion for CORDStrom platform - Investing.com
Patent Win: INmune Bio's Revolutionary Cell Therapy Secures 20+ Years Protection - Stock Titan
INmune Bio (INMB) Partners with CGT Catapult for Large-Scale Cel - GuruFocus
INmune Bio Partners with Cell and Gene Therapy Catapult - MSN
INmune Bio (INMB) Partners to Enhance Cell Therapy Production - GuruFocus
INmune Bio in pact with Cell and Gene Therapy Catapult (INMB) - Seeking Alpha
INmune Bio, CGT Catapult Partner To Scale CORDStrom Manufacturing For Commercial Launch - Nasdaq
INmune Bio Collaborating With Cell and Gene Therapy Catapult to Scale Manufacturing - MarketScreener
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness - The Manila Times
INmune Bio's Game-Changing Partnership Accelerates CORDStrom Production for 4,000 RDEB Patients - Stock Titan
Inmune Bio Presents Alzheimer’s Trial Data at Conference - TipRanks
INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Price Target from Brokerages - Defense World
Trend Tracker for (INMB) - news.stocktradersdaily.com
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - ADVFN
INmune Bio Presents MINDFuL Trial Data At AD/PD 2025 - Nasdaq
Inmune Bio Inc Azioni (INMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.76%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):